Higher parity, obesity and depression at the time of delivery linked to bothersome postpartum urinary symptoms: Study

Higher parity, obesity and depression at the time of delivery linked to bothersome postpartum urinary symptoms suggests a study published in the Urogynecology.

Urinary incontinence is a common postpartum morbidity that negatively affects quality of life. This study aimed to identify factors associated with persistent (ie, 12 months postpartum) bothersome urinary symptoms, including stress urinary incontinence (SUI) and urgency urinary incontinence (UUI), and explore their association with mental health in medically underserved communities. This was a cross-sectional analysis of a prospective study of individuals enrolled into “extending Maternal Care After Pregnancy,” a program providing 12 months of postpartum care to individuals with health disparities. Patients were screened at 12 months for urinary dysfunction, anxiety, and depression using the Urinary Distress Index-6, Generalized Anxiety Disorder-7, and Edinburgh Postnatal Depression Scale, respectively. Bivariate and multivariable logistic regression analyses were performed for at-least-somewhat-bothersome SUI versus no-SUI, UUI versus no-UUI, and for bothersome versus asymptomatic urinary symptoms, using demographic and peripartum and postpartum variables as associated factors.Results : Four hundred nineteen patients provided data at median 12 months postpartum. Patients were 77% Hispanic White and 22% non-Hispanic Black. After multivariable analysis, SUI (n = 136, 32.5%) was significantly associated with increasing body mass index at the time of delivery and greater depression screening scores. Fetal birthweight, mode of delivery, degree of laceration, and breastfeeding status were not associated. Urgency urinary incontinence (n = 69, 16.5%) was significantly associated with increasing parity and higher anxiety screening scores. Similarly, participants with urinary symptom bother had significantly greater parity and higher anxiety screening scores. At 12 months postpartum, bothersome urinary symptoms and incontinence were quite common. Since these are treatable, postpartum screening for urinary complaints—and associated anxiety and depression—is essential, as is assisting patients in achieving a healthy weight

Reference:

Bhandari Randhawa, Sonia MD; Rizkallah, Andrea MD; Nelson, David B. MD; Duryea, Elaine L. MD; Spong, Catherine Y. MD; Pruszynski, Jessica E. PhD; Rahn, David D. MD. Factors Associated With Persistent Bothersome Urinary Symptoms and Leakage After Pregnancy. Urogynecology ():10.1097/SPV.0000000000001528, April 30, 2024. | DOI: 10.1097/SPV.0000000000001528

Keywords:

Higher parity, obesity, depression, delivery, bothersome, postpartum urinary, symptoms, Study , Bhandari Randhawa, Sonia MD; Rizkallah, Andrea MD; Nelson, David B. MD; Duryea, Elaine L. MD; Spong, Catherine Y. MD; Pruszynski, Jessica E. PhD; Rahn, David D. MD

Powered by WPeMatico

Gilead Sciences inks pacts with Dr Reddy’s Labs, Emcure, Hetero and 3 others for HIV drug Lenacapavir

Foster City: Gilead Sciences, Inc. has announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries, which are primarily low- and lower-middle income countries.

The generic companies that will manufacture and supply lenacapavir to the 120 countries are Dr. Reddy’s Laboratories Limited, Emcure, Eva Pharma, Ferozsons Laboratories Limited, Hetero and Mylan, a subsidiary of Viatris.

The agreements were signed in advance of any global regulatory submissions to enable these countries to quickly introduce generic versions of lenacapavir for HIV prevention, if approved.

” The agreements advance Gilead’s strategy to enable broad, sustainable access to lenacapavir for pre-exposure prophylaxis (PrEP) globally if it is approved, and align with Gilead’s vision of ending the HIV epidemic for everyone, everywhere. Gilead will support low-cost access to the drug in high-incidence, resource-limited countries through a two-part strategy: establishing a robust voluntary licensing program, and planning to provide Gilead-supplied product at no profit to Gilead until generic manufacturers are able to fully support demand. Additionally, the agreements cover not only lenacapavir for HIV prevention (pending approval), but also lenacapavir for HIV treatment in heavily treatment-experienced (HTE) adults with multi-drug resistant HIV,“ the Company stated in a BSE filing.

“Given the transformative potential of lenacapavir for prevention, our focus is on making it available as quickly and broadly as possible where the need is greatest,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead. “Gilead teams have been working with urgency to bring on high-volume generic manufacturers now, so that we can ensure a rapid transition to these voluntary license partners after lenacapavir for PrEP is approved.”

To provide Gilead-supplied lenacapavir until generic versions are available, Gilead is prioritizing registration in 18 countries that represent about 70% of the HIV burden in the countries named in the license. These countries, identified in consultation with external partners, are Botswana, Eswatini, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, Philippines, Rwanda, South Africa, Tanzania, Thailand, Uganda, Vietnam, Zambia and Zimbabwe.

Earlier this year, two pivotal Phase 3 trials of lenacapavir for PrEP, PURPOSE 1 and PURPOSE 2, were both unblinded early because they met their key efficacy endpoints of superiority of twice-yearly lenacapavir to once-daily oral Truvada and background HIV incidence. PURPOSE 1 enrolled cisgender women in South Africa and Uganda, and PURPOSE 2 enrolled cisgender men, transgender men, transgender women and non-binary individuals in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the United States who have sex with partners assigned male at birth.

As per the release, based on data from these trials, Gilead will begin a series of global regulatory filings by the end of 2024. For high-incidence, resource-limited countries, Gilead is exploring frameworks such as the European Medicines Agency’s EU Medicines for All with the aim of expediting both national regulatory procedures and the attainment of WHO prequalification. Updates on regulatory filings for lenacapavir for PrEP will be shared as discussions with regulatory bodies progress.

Powered by WPeMatico

NBE Empanels 9 institutes for providing Skill Lab training to trainees, check complete list here

New Delhi: To upgrade and enhance its trainees’ skills, the National Board of Examination (NBE) has empanelled 9 institutes/hospitals to provide skill lab training to its Trainees pursuing various courses with the NBEMS.

According to the notification issued in this regard, the NBE has released the list of the 9 institutes stating that in its endeavour to upgrade and enhance the skills of NBEMS trainees, NBEMS has empanelled the following institutes/hospitals to provide the skill lab training in various courses:-

S. No

Skill Lab & Address
1

Deenanath Mangeshkar Hospital and Research Center’s Simulation Center, 8+13/2, Erandawane, Near Mhatre Bridge, Pune Maharashtra-411004
2

Skill & Simulation Lab at KIMSHEALTH, Anayara PO, Post Box No.1, Trivandrum, Kerala 695029
3

Medical Simulation Laboratory at DY Patil University, Sector 7, Nerul Navi Mumbai, Maharashtra 400706
4

GSL Smart Lab at GSL Medical College & General Hospital, NH-16, Lakshmipuram, Rajahmundry, Andhra Pradesh 533296
5

Skill Development Unit at Mahatma Gandhi Mission’s Medical College & Hospital, N-6, CIDCO, Aurangabad-431003, Maharashtra
6

School of Experiential Learning & Simulation Centre (SEL & SC) of DMIHER(DU), Sawangi (Meghe), Wardha-442007 Maharashtra
7

Apollo Simulation Centre, No. 64, Vanagaram to Ambattur, Yadaval St, Off Poonamallee High Road, Vanagaram, Chennai, Tamil Nadu 600095
8

Muljibhai Patel Society for Research in Nephro-Urology at Muljibhai Patel Urological Hospital, Nadiad, Gujarat-387001 
9

JSS AHER Skill and Simulation Centre at JSS Medical College, Third Floor, Old OPD Block, JSS Hospital M G Road, Mysuru, Karnataka 570004

In its notice, the NBE further mentioned, “the Skill Lab shall offer the courses/programme at discounted prices for NBEMS trainees.”

“NBEMS trainees are encouraged to utilize the skill lab to enhance their clinical skills as per their course curriculum and availability of suitable Skill lab courses at these Institutes. Please note that attending these skill lab courses is not a mandatory requirement for NBEMS trainees. NBEMS trainees who are attending these Skill Lab courses/programme have to bear all the cost at their level only. NBEMS shall not be responsible for the cost proposed by the skill labs,” NBE informed its trainees.

“NBEMS shall not be responsible or interfere in any dispute arising between the applicant candidate & Skill lab,” the notice said.

“For any query related to Skill Lab courses/programmes, please contact the concerned Lab. NBEMS shall not entertain such queries related to availability of Skill lab courses, Skill lab fees, etc, “the notice added.

To view the official Notice, Click here : https://medicaldialogues.in/pdf_upload/nbems20241007395794jpg-255161.pdf

Powered by WPeMatico

NCDRC orders JnJ to pay Rs 35 lakh compensation for faulty hip replacement device

In a significant ruling, the National Consumer Disputes Redressal Commission (NCDRC) has ordered Johnson & Johnson Limited to compensate a consumer with Rs 35 lakh for medical complications arising from the company’s defective hip replacement device. The commission, comprised of presiding member Ram Surat Maurya along with members Subhash Chandra and Inder Jit Singh, was hearing a complaint filed by Purushotham Lohia, who had sought Rs 5 crore in compensation after suffering ongoing health issues following the use of the DePuy’s Acetabular System Resurfacing (ASR XL) hip implant.

According to Lohia, he underwent total hip replacement surgery with the ASR XL device. It said that though the opposite parties reimbursed Rs 25 lakh for Lohia’s revision surgery, in May 2017, no compensation was paid for his losses.

For more details, click the link below

Apex Consumer Court slaps Rs 35 lakh compensation on Johnson & Johnson for faulty hip replacement device

Powered by WPeMatico

Eliminating tobacco smoking could help increase life expectancy by 2050, study suggests

Accelerating the decline in tobacco smoking globally, by decreasing smoking prevalence from current levels to 5% everywhere, could increase life expectancy and prevent millions of premature deaths by 2050, according to a study from the Global Burden of Disease, Injuries and Risk Factors (GBD) Tobacco Forecasting Collaborators published in The Lancet Public Health journal.

Powered by WPeMatico

One million people who never regularly smoked now vape in England, finds study

The number of adults vaping in England who have never regularly smoked has increased sharply since 2021, when disposable e-cigarettes first became popular, according to a new study by UCL researchers.

Powered by WPeMatico

Banning tobacco sales among young people could prevent 1.2 million lung cancer deaths, study suggests

Creating a generation of people who never smoke could prevent 1.2 million deaths from lung cancer globally, according to a study led by researchers from the University of Santiago de Compostela, the International Agency for Research on Cancer (IARC), and global collaborators published in The Lancet Public Health journal.

Powered by WPeMatico

Exploring health care site- and patient-related factors influence COVID-19 vaccination completion rates

The COVID-19 vaccine, introduced in December 2022, played a critical role in reducing mortality and morbidity related to the pandemic globally. Yet, by 2023, only 70% of the US population had completed the primary vaccination series. While factors such as race/ethnicity, socio-economic status, geography and political affiliations have been linked to vaccination rates, its relationship with characteristics of health care delivery sites like community health care centers (CHCs), has not been explored. CHCs, which provide comprehensive primary care to low-income populations, including COVID-19 vaccines, are key players in health care delivery.

Powered by WPeMatico

Gene activation linked to severity of a rare lung cancer

Pulmonary carcinoids are rare tumors of the lung with extremely different clinical courses. In many patients, they behave like benign tumors; surgical removal of the tumor leads to a complete cure. However, some patients experience aggressive growth and spread (metastasis) of the tumor with poor chances of recovery. The biological causes of these different forms of the disease are still unknown.

Powered by WPeMatico

CCI approves acquisition of Bharat Serums and Vaccines by Mankind Pharma

New Delhi: Competition Commission of India has approved the acquisition of Bharat Serums and Vaccines Limited by Mankind Pharma Ltd.

The proposed transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines Limited (BSV) by Mankind Pharma Ltd. (Mankind) (Proposed Combination).

Mankind is a public listed company and is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical finished dosage formulations (FDFs) across various acute and chronic therapeutic areas, as well as several consumer healthcare products such as condoms, emergency contraceptives, pregnancy tests, vitamins, minerals, nutrients, antacids and anti-acne preparations segments. Through its subsidiaries, Mankind is also engaged in, inter alia, the manufacture and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediaries, and packaging products for pharmaceutical products.

BSV, along with its subsidiaries, is engaged in research, development, licensing, manufacturing, importing, exporting, marketing and distribution of: (a) FDFs and APIs; (b) biotech and biological formulations and/or API; (c) food and health supplements; (d) medical devices; and (e) ayurvedic medicines; in each case, in the therapeutic areas such as gynaecology, in-vitro fertilisation, critical care and/or emergency medicines for human use. In India, the activities of BSV (including its wholly owned Indian subsidiary, BSV Pharma Private Limited, which is in the process of merging with BSV) are limited to developing, manufacturing, and marketing a range of biological, biotech, and pharmaceutical products in the therapeutic areas of women’s health, critical care, IUI-IVF, and emergency medicine.

Detailed order of the Commission will follow.

Read also: Mankind Pharma board to consider fund raising

Powered by WPeMatico